The post NVIDIA DLSS 4.5 Launches With 5x More Compute Power for Gaming AI appeared on BitcoinEthereumNews.com. Luisa Crawford Jan 14, 2026 14:30 NVIDIA unveilsThe post NVIDIA DLSS 4.5 Launches With 5x More Compute Power for Gaming AI appeared on BitcoinEthereumNews.com. Luisa Crawford Jan 14, 2026 14:30 NVIDIA unveils

NVIDIA DLSS 4.5 Launches With 5x More Compute Power for Gaming AI

2026/01/15 13:27
Okuma süresi: 3 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen crypto.news@mexc.com üzerinden bizimle iletişime geçin.


Luisa Crawford
Jan 14, 2026 14:30

NVIDIA unveils DLSS 4.5 at CES 2026 with second-gen transformer model, 6x frame generation, and neural shading upgrades for RTX GPUs.

NVIDIA dropped DLSS 4.5 at CES 2026, packing a second-generation transformer model that uses 5x more compute than its predecessor. The upgrade targets the 250+ games already running DLSS 4, with major upcoming titles like PRAGMATA and Resident Evil Requiem queued for integration.

The company’s stock sits at $185.81 as of January 13, with shares up 0.47% over 24 hours and a market cap hovering around $4.51 trillion. This release comes as NVIDIA navigates fresh regulatory developments, with the U.S. recently approving H200 chip exports to China under certain conditions.

What’s Actually New

The second-gen transformer model represents the technical meat here. NVIDIA trained it on an expanded dataset, giving the AI better context awareness for scene analysis and smarter pixel sampling. The practical result? Performance Mode now matches or beats native resolution quality, while Ultra Performance becomes genuinely usable for 4K gaming.

Dynamic Multi Frame Generation is the other headline feature. Rather than locking frame generation at a fixed multiplier, the system now shifts automatically based on scene demands. A 6x mode for RTX 50 Series GPUs arrives this spring through Streamline Plugin updates.

Neural Shading Gets Faster

The RTX Neural Texture Compression SDK hit version 0.9 with some notable benchmarks. Block Compression 7 encoding runs 6x faster than before, while inference speed jumped 20% to 40% compared to version 0.8. Developers can now save up to 7x system memory without tanking frame rates.

RTX Kit update 2026.1 bundles these improvements with bug fixes for the Neural Shaders SDK and adds Vulkan support for RTX Hair rendering.

ACE Expands AI Character Options

NVIDIA’s ACE platform now supports the Nemotron Nano 9B V2 model through an In-game Inferencing SDK plugin. The model handles real-time reasoning for non-scripted NPC interactions. Developers can disable intermediate reasoning traces to speed up responses when precision matters less than snappiness.

Qwen3-8B support expanded to include 4B and 600M variants, giving studios more flexibility when balancing memory usage against response quality.

Developer Timeline

DLSS 4.5 Super Resolution is available now through the Streamline Plugin. The 6x Dynamic Multi Frame Generation mode hits this spring. Nsight Graphics 2025.5 already shipped with dynamic shader editing and RTX Hair visualization in the Ray Tracing Inspector.

For NVIDIA investors watching the gaming segment, adoption velocity matters. DLSS 4 became the company’s fastest-adopted gaming tech ever. Whether 4.5 maintains that momentum—particularly with the 6x mode requiring RTX 50 Series hardware—will show up in developer integration rates over the coming quarters.

Image source: Shutterstock

Source: https://blockchain.news/news/nvidia-dlss-4-5-launches-5x-compute-power-gaming-ai

Piyasa Fırsatı
4 Logosu
4 Fiyatı(4)
$0.009508
$0.009508$0.009508
-1.44%
USD
4 (4) Canlı Fiyat Grafiği

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen crypto.news@mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Paylaş
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Paylaş
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Paylaş
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage